Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co‐infected patients

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Viral Hepatitis

• Publication date

  2015-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jvh.12226PMID 24506344PMCID PMC4127161
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma Proteome Analysis Reveals Overlapping, yet Distinct Mechanisms of Immune Activation in Chronic HCV and HIV Infections

  2013cited by this paper
• Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

  2013cited by this paper
• Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients

  2013cited by this paper
• Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.

  2013cited by this paper
• A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy

  2012cited by this paper
• Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis.

  2012cited by this paper
• Cytokine Levels and Histopathology in Chronic Hepatitis B and Chronic Hepatitis C

  2012cited by this paper
• Reduced Naive CD 4 T Cell Numbers and Impaired Induction of CD 27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection

  2011cited by this paper
• Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients.

  2011cited by this paper
• Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients.

  2011cited by this paper
• Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection.

  2011cited by this paper
• Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients.

  2010cited by this paper
• Innate immunity and chronic immune activation in HCV/HIV-1 co-infection.

  2010cited by this paper
• Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1.

  2010cited by this paper
• Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis.

  2009cited by this paper
• Interleukin-1 participates in the progression from liver injury to fibrosis.

  2009cited by this paper
• High Levels of Chronic Immune Activation in the T-Cell Compartments of Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1 and on Highly Active Antiretroviral Therapy Are Reverted by Alpha Interferon and Ribavirin Treatment

  2009cited by this paper
• Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.

  2009cited by this paper
• Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic)

  2008cited by this paper
• Interferon-gamma exacerbates liver damage, the hepatic progenitor cell response and fibrosis in a mouse model of chronic liver injury.

  2007cited by this paper
• Elevated serum levels of interferon- gamma -inducible protein-10 in patients coinfected with hepatitis C virus and HIV.

  2007cited by this paper
• Differential antiviral effect of PEG-interferon-α-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients

  2007cited by this paper
• Mechanisms of Disease: HCV-induced liver injury

  2007cited by this paper
• Effect of the interleukin‐6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients

  2007cited by this paper
• Contributions to Hepatic Fibrosis in HIV-HCV Coinfected and HCV Monoinfected Patients

  2006cited by this paper
• Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy

  2006cited by this paper
• Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

  2005cited by this paper
• Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection

  2005cited by this paper
• Naive HIV/HCV-Coinfected Patients Have Higher Intrahepatic Pro-Inflammatory Cytokines than Coinfected Patients Treated with Antiretroviral Therapy

  2005cited by this paper
• Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C.

  2005cited by this paper
• Transforming growth factor beta in hepatitis C virus infection: In vivo and in vitro findings

  2003cited by this paper
• In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

  2003cited by this paper
• Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis

  2002cited by this paper
• Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells.

  2001cited by this paper
• INVOLVEMENT OF TRAIL/TRAIL-R INTERACTION IN IFN-α-INDUCED APOPTOSIS OF DAUDI B LYMPHOMA CELLS

  2001cited by this paper
• Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

  2000cited by this paper
• Fibroblast growth factor-2.

  2000cited by this paper
• Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients

  2000cited by this paper
• Fibroblast growth factor-2.

  2000cited by this paper
• Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection.

  1999cited by this paper
• Histological and virological long‐term outcome in patients treated with interferon‐α2b and ribavirin for chronic hepatitis C

  1999cited by this paper
• Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

  1999cited by this paper
• Long‐term administration of interferon‐α in non‐responder patients with chronic hepatitis C: follow‐up of liver fibrosis over 5 years

  1999cited by this paper
• Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

  1999cited by this paper
• Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation

  1997cited by this paper
• Consensus symposium on combined antiviral therapy; overview of interferon and IL-2 combinations for the treatment of HIV infection.

  1996cited by this paper
• Advances in liver biopsy diagnosis.

  1994cited by this paper
• Three open-label studies of oral interferon alpha in the treatment of HIV disease.

  1994cited by this paper
• Induction of circulating IL-1 receptor antagonist by IFN treatment.

  1993cited by this paper
• Clinical and histological evaluation of interferon alfa-2b in the treatment of chronic hepatitis C.

  1993cited by this paper
• Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial.

  1992cited by this paper
• Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.

  1991cited by this paper
• Biochemical characterization of a gamma interferon-inducible cytokine (IP-10)

  1987cited by this paper

• The Dual Role of IP-10/CXCL10 in Liver Injury: From Pathogenic Mediator to Clinical Biomarker and Therapeutic Target

  2026cites this paper
• Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis

  2022cites this paper
• Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in HIV–HCV-Coinfected Individuals

  2020cites this paper
• Profiling Circulating Inflammation and Microbial Translocation Biomarkers Associated with Advanced Liver Fibrosis in HIV/HCV Coinfected Persons

  2020cites this paper
• СОСТОЯНИЕ ИММУНИТЕТА У ВИЧ-ИНФИЦИРОВАННЫХ ПАЦИЕНТОВ, КОИНФИЦИРОВАННЫХ ВИРУСОМ ГЕПАТИТА C

  2019cites this paper
• Immune Disorders in HIV-Infected Patients Coinfected with Hepatitis C Virus

  2018cites this paper
• Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C

  2018cites this paper
• Persistent Replication of HIV, Hepatitis C Virus (HCV), and HBV Results in Distinct Gene Expression Profiles by Human NK Cells

  2018cites this paper
• IMMUNE STATUS IN HIVINFECTED PATIENTS COINFECTED WITH HEPАTITIS C VIRUS (HCV)

  2018cites this paper
• PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics

  2017cites this paper
• Cognitive Restructuring Based on Metaphor Therapy to Challenge the Irrational Beliefs of Drug Addicts Undergoing Buprenorphine Treatment

  2016cites this paper
• Association of immune response parameters with virological response in hepatitis C virus patients treated with pegylated consensus interferon.

  2016cites this paper
• Hepatitis C virus‐induced myeloid‐derived suppressor cells regulate T‐cell differentiation and function via the signal transducer and activator of transcription 3 pathway

  2016cites this paper
• Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report

  2014cites this paper